JOINT FDA ADVISORY COMMITTEE CONFIRMS OTC PRILOSEC® (OMEPRAZOLE) SAFETY AND EFFICACY

CINCINNATI and WILMINGTON, Del., October 20, 2000 -- Procter & Gamble and AstraZeneca today announced that a joint session of the Nonprescription Drugs Advisory Committee and Gastroenterological Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) recommended that PRILOSEC (omeprazole), the world's top-selling drug, can be safe and effective as an over-the-counter (OTC) preventative treatment for heartburn. The joint committees requested additional data.

"We are encouraged by the outcome of today's meeting. It's quite common for the committee to request additional data for a first-in-class Rx-to-OTC switch," says Tom Blinn, vice president of OTC healthcare at Procter & Gamble, which will be marketing and distributing the drug in the U.S. "We will work closely with the FDA to provide the data requested."

The committee based its discussions on the results of OTC clinical trials involving more than 11,000 patients. Available worldwide as a prescription medicine for more than a decade, PRILOSEC has been used in more than 400 million patient treatments and studied in more than 1,350 clinical trials.

More than 50 million Americans -- or 40% of the adult population -- suffer from heartburn. A variety of dietary and lifestyle factors such as spicy foods or stress can contribute to heartburn and can negatively impact normal activities and sleep.

Current OTC therapies include antacids, which are indicated for temporary relief of heartburn, and H2 blockers, which are indicated for relief of heartburn and prevention of heartburn associated with food and beverage. Antacids neutralize stomach acid with relief lasting up to 3 hours, while H2 blockers may reduce acid production for up to 12 hours. PRILOSEC belongs to a unique class of drugs called proton pump inhibitors (PPIs) currently available only by prescription. PPIs like PRILOSEC deactivate the acid pumps to significantly reduce acid secretion for up to 24 hours.

"We believe that an OTC version of PRILOSEC will provide consumers with the possibility of up to 24-hour heartburn prevention with just one pill," says Mark Mallon, vice president, gastrointestinal therapeutic area, AstraZeneca.

Prescription PRILOSEC, marketed globally by AstraZeneca, is indicated for several different uses encompassing a broad range of acid-related gastrointestinal diseases, including heartburn and other symptoms associated with gastroesophageal reflux disease. Individual results may vary. The most common side effects of prescription PRILOSEC are headache, diarrhea and abdominal pain. The full prescribing information for prescription PRILOSEC is available at www.prilosec-us.com and www.purplepill.com . Side effects for the OTC version of PRILOSEC were transient and mild compared to placebo.

Currently, PRILOSEC is available without a prescription in Sweden. In the United States, AstraZeneca and Procter & Gamble have worked closely to develop the clinical data needed for the Rx-to-OTC switch. Procter & Gamble, which has a long history of successfully bringing quality consumer health care products to market, will handle the marketing and distribution of nonprescription PRILOSEC in the US.

Further enquires to: